Literature DB >> 27057434

Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.

Ali Roghanian1, Mark S Cragg2, Björn Frendéus3.   

Abstract

Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.

Entities:  

Keywords:  CD32B; FcgRIIB; immunotherapy; mAb resistance; monoclonal antibody; therapyrituximab

Year:  2015        PMID： 27057434      PMCID： PMC4801439          DOI： 10.1080/2162402X.2015.1069939

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.

Authors:  Nadine van Montfoort; Peter A C 't Hoen; Sara M Mangsbo; Marcel G M Camps; Peter Boross; Cornelis J M Melief; Ferry Ossendorp; J Sjef Verbeek
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

2.  Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Authors:  Ali Roghanian; Ingrid Teige; Linda Mårtensson; Kerry L Cox; Mathilda Kovacek; Anne Ljungars; Jenny Mattson; Annika Sundberg; Andrew T Vaughan; Vallari Shah; Neil R Smyth; Bhavwanti Sheth; H T Claude Chan; Zhan-Chun Li; Emily L Williams; Giusi Manfredi; Robert J Oldham; C Ian Mockridge; Sonya A James; Lekh N Dahal; Khiyam Hussain; Björn Nilsson; J Sjef Verbeek; Gunnar Juliusson; Markus Hansson; Mats Jerkeman; Peter W M Johnson; Andrew Davies; Stephen A Beers; Martin J Glennie; Björn Frendéus; Mark S Cragg
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 3.  Fcgamma receptors as regulators of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

4.  Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Authors:  Thomas R W Tipton; Ali Roghanian; Robert J Oldham; Matthew J Carter; Kerry L Cox; C Ian Mockridge; Ruth R French; Lekh N Dahal; Patrick J Duriez; Philip G Hargreaves; Mark S Cragg; Stephen A Beers
Journal:  Blood       Date:  2015-01-28       Impact factor: 22.113

5.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

6.  Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Authors:  Sean H Lim; Andrew T Vaughan; Margaret Ashton-Key; Emily L Williams; Sandra V Dixon; H T Claude Chan; Stephen A Beers; Ruth R French; Kerry L Cox; Andrew J Davies; Kathleen N Potter; C Ian Mockridge; David G Oscier; Peter W M Johnson; Mark S Cragg; Martin J Glennie
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

7.  Sensitizing protective tumor microenvironments to antibody-mediated therapy.

Authors:  Christian P Pallasch; Ilya Leskov; Christian J Braun; Daniela Vorholt; Adam Drake; Yadira M Soto-Feliciano; Eric H Bent; Janine Schwamb; Bettina Iliopoulou; Nadine Kutsch; Nico van Rooijen; Lukas P Frenzel; Clemens M Wendtner; Lukas Heukamp; Karl Anton Kreuzer; Michael Hallek; Jianzhu Chen; Michael T Hemann
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

8.  Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).

Authors:  Chern Siang Lee; Margaret Ashton-Key; Sergio Cogliatti; Stephanie Rondeau; Shu-Fang Hsu Schmitz; Michele Ghielmini; Mark S Cragg; Peter Johnson
Journal:  Br J Haematol       Date:  2014-08-21       Impact factor: 6.998

9.  Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.

Authors:  Joel F G Cohen-Solal; Lydie Cassard; Emilie M Fournier; Shannon M Loncar; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Dermatol Res Pract       Date:  2010-06-28

10.  Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

Authors:  Andrew T Vaughan; Chisako Iriyama; Stephen A Beers; Claude H T Chan; Sean H Lim; Emily L Williams; Vallari Shah; Ali Roghanian; Bjorn Frendéus; Martin J Glennie; Mark S Cragg
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113
  10 in total
  3 in total

1.  Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Authors:  Vivian Changying Jiang; Yang Liu; Alexa Jordan; Angela Leeming; Joseph McIntosh; Shengjian Huang; Rongjia Zhang; Qingsong Cai; Zhihong Chen; Yijing Li; Yuxuan Che; Lei Nie; Ingrid Karlsson; Linda Mårtensson; Mathilda Kovacek; Ingrid Teige; Björn Frendéus; Michael Wang
Journal:  J Hematol Oncol       Date:  2022-04-11       Impact factor: 17.388

2.  Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Authors:  Sarah E Arthur; Aixiang Jiang; Bruno M Grande; Miguel Alcaide; Razvan Cojocaru; Christopher K Rushton; Anja Mottok; Laura K Hilton; Prince Kumar Lat; Eric Y Zhao; Luka Culibrk; Daisuke Ennishi; Selin Jessa; Lauren Chong; Nicole Thomas; Prasath Pararajalingam; Barbara Meissner; Merrill Boyle; Jordan Davidson; Kevin R Bushell; Daniel Lai; Pedro Farinha; Graham W Slack; Gregg B Morin; Sohrab Shah; Dipankar Sen; Steven J M Jones; Andrew J Mungall; Randy D Gascoyne; Timothy E Audas; Peter Unrau; Marco A Marra; Joseph M Connors; Christian Steidl; David W Scott; Ryan D Morin
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

3.  FcγRIIB is a T cell checkpoint in antitumor immunity.

Authors:  Clara R Farley; Anna B Morris; Marvi Tariq; Kelsey B Bennion; Sayalee Potdar; Ragini Kudchadkar; Michael C Lowe; Mandy L Ford
Journal:  JCI Insight       Date:  2021-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.